Author's response to reviews

Title: Local control of metastatic lung cancer is worse than that of primary lung cancer in patients treated with stereotactic body radiotherapy

Authors:

Takaya Yamamoto (priere_for@yahoo.co.jp)
Keiichi Jingu (kjingu-jr@rad.med.tohoku.ac.jp)
Yuko Shirata (quldoktu@yahoo.co.jp)
Masashi Koto (koto@nirs.go.jp)
Haruo Matsushita (harumatsu2001@yahoo.co.jp)
Toshiyuki Sugawara (sugatosi772288@yahoo.co.jp)
Masaki Kubozono (satoharuapple@yahoo.co.jp)
Rei Umezawa (reirei513@hotmail.com)
Keiko Abe (abe-k@rad.med.tohoku.ac.jp)
Youjirou Ishikawa (y02614111@yahoo.co.jp)
Maiko Kozumi (drmk2009@yahoo.co.jp)
Noriyoshi Takahashi (noriyoshi.08.25@gmail.com)
Ken Takeda (takedak41@yahoo.co.jp)
Yoshihiro Takai (takaiken@ic-net.or.jp)

Version: 2 Date: 6 September 2013

Author's response to reviews:

September 5, 2013

Dear Mr. Dafne Solera, Executive Editor, BioMed Central cancer.

On behalf of all the authors, I am submitting a manuscript entitled "Local control of metastatic lung cancer is worse than that of primary lung cancer in patients treated with stereotactic ablative radiotherapy" for consideration for publication in the BMC cancer as a Scientific Article.

In this manuscript, we investigated treatment outcomes for primary lung cancer and metastatic lung tumors after stereotactic body radiotherapy (SBRT) in patients treated in our institution for 11 years. We analyzed prognostic factors with an association with local control (LC) and overall survival (OS), with the goal of maximizing the benefit/toxicity ratio of SBRT. Tumor diameter and tumor origin (primary lung cancer or metastatic lung tumor) were found to be independent significant factors for both LC and OS in multivariate analysis. It has previously been shown that metastatic lung tumor is a significant factor for unfavorable LC in short-term follow-up, but our results are based on much longer follow-up periods and analyses of both LC and OS. We also provide a thorough discussion on why a metastatic lung tumor is an unfavorable factor after SBRT.

We hope that the manuscript will be suitable for publication in the BMC cancer
and we look forward to your reply.

Sincerely,

Takaya Yamamoto M.D.
Department of Radiation Oncology, Tohoku University
1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574 Japan
Tel:+81-22-717-7312
Fax:+81-22-717-7316
E-mail: priere_for@yahoo.co.jp